文献速递腹部技术与安全USMR

高危人群肝细胞癌监测策略的影像学解读

Surveillance for Hepatocellular Carcinoma in Patients at High Risk.
PubMed 文献 · Radiographics · 2026-01-01

本文综述了肝细胞癌高危人群的监测策略。现行指南推荐每半年超声联合血清甲胎蛋白检测作为标准方案,但超声在肥胖、脂肪肝及晚期肝硬化患者中敏感性欠佳。研究支持在高危亚组中采用生物标志物组合和简化MRI方案,以实现个体化风险分层监测。

要点

  • 超声联合甲胎蛋白为常规监测手段,但需注意肥胖、脂肪肝、晚期肝硬化患者的敏感性不足
  • LI-RADS 2024将超声检查质量评估纳入管理决策,报告中应体现检查质量
  • 对超声质量不佳或高危亚组患者,可考虑简化MRI或生物标志物组合等替代策略

核心结论

  • 监测效率强烈依赖于个体肝细胞癌风险、影像成本、监测使用率及社会支付意愿阈值,应摒弃「一刀切」策略,采用个体化风险适应性监测模式

研究设计与样本

  • 本文为综述,综合现有证据以识别目标人群、评估现有影像学方法的诊断效能、考量成本效益、新兴技术及实施监测方案的真实世界障碍

关键影像表现/征象

  • 本文未涉及具体影像征象的描述,主要讨论监测策略框架及LI-RADS 2024对超声检查质量评估与报告的整合

诊断标准与关键数值

  • 现行指南推荐对多数高危患者采用每半年超声联合血清甲胎蛋白检测作为标准监测方案
  • 超声监测可改善早期肿瘤检出与生存,但在肥胖、肝脂肪变性及晚期肝硬化等特定高危亚组中敏感性欠佳
  • 生物标志物组合与简化MRI方案在经适当风险分层的人群中显示出更高的敏感性及良好的成本效益

临床应用与阅片要点

  • 在临床实践中,监测使用率仍不理想,受患者、医生及系统层面的多重障碍影响,影像科医生应关注检查质量评估并将其纳入报告
  • 对肥胖、脂肪肝或晚期肝硬化患者,超声检查阴性结果需谨慎解读,可考虑进一步影像学评估

局限性

  • 超声监测在肥胖、肝脂肪变性及晚期肝硬化等特定高危亚组中敏感性欠佳

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide and most often arises in patients with chronic liver disease and cirrhosis. Since curative treatment options are largely limited to early-stage disease, effective surveillance strategies are essential to improve outcomes. Current guidelines recommend semiannual US combined with serum α-fetoprotein level testing as the standard surveillance approach for most patients at high risk. Liver Imaging Reporting and Data System 2024 guidance provides a structured framework for interpretation of surveillance US and highlights the importance of examination quality assessment and reporting by incorporating it into the management decision-making algorithm. US surveillance improves early tumor detection and survival but demonstrates suboptimal sensitivity in certain high-risk subgroups, particularly patients with obesity, hepatic steatosis, and advanced cirrhosis. Growing evidence supports the use of alternative strategies including biomarker panel results and abbreviated MRI protocols in selected patient subgroups because these approaches demonstrate higher sensitivity and favorable cost-effectiveness when applied to appropriately risk-stratified populations. Furthermore, cost-effectiveness analyses consistently indicate that surveillance efficiency strongly depends on individual HCC risk, imaging costs, surveillance use, and societal willingness-to-pay thresholds, supporting a departure from uniform "one-size-fits-all" strategies in favor of personalized, risk-adapted surveillance paradigms. Despite advances in diagnostic performance, surveillance use remains suboptimal in clinical practice due to patient-, provider-, and system-level barriers. The authors aim to synthesize current evidence on HCC surveillance including identifying target populations; evaluating the diagnostic performance of available modalities; and considering cost-effectiveness, emerging technologies, and real-world barriers to implementation of surveillance protocols.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. Fowler, Kamaya, Rodgers, et al. Surveillance for Hepatocellular Carcinoma in Patients at High Risk. Radiographics. 2026. PMID: 42690964. doi:10.1148/rg.260010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。